Effect of high-intensity interval training in physiotherapy primary care for patients with inflammatory arthritis: the ExeHeart randomised controlled trial.
Arthritis, Psoriatic
Arthritis, Rheumatoid
Cardiovascular Diseases
Physical Therapy Modalities
Spondylitis, Ankylosing
Journal
RMD open
ISSN: 2056-5933
Titre abrégé: RMD Open
Pays: England
ID NLM: 101662038
Informations de publication
Date de publication:
18 Jan 2024
18 Jan 2024
Historique:
received:
27
06
2023
accepted:
25
12
2023
medline:
20
1
2024
pubmed:
20
1
2024
entrez:
19
1
2024
Statut:
epublish
Résumé
To assess the effect of high-intensity interval training (HIIT) delivered in physiotherapy primary care on the primary outcome of cardiorespiratory fitness (CRF) in patients with inflammatory arthritis (IA). Additionally, to explore the effects of HIIT on secondary outcomes, including cardiovascular disease (CVD) risk factors and disease activity. Single-blinded randomised controlled trial with 60 patients randomly assigned to either a control group receiving usual care or an exercise group receiving usual care and 12 weeks of individualised HIIT at 90%-95% peak heart rate. Outcomes were assessed at baseline, 3 months and 6 months post baseline and included CRF measured as peak oxygen uptake (VO Intention-to-treat analysis demonstrated a significant between-group difference in VO After 12 weeks of supervised HIIT delivered in physiotherapy primary care, patients with IA demonstrated a favourable improvement in CRF, with sustained effects at 6-month follow-up. NCT04922840.
Identifiants
pubmed: 38242550
pii: rmdopen-2023-003440
doi: 10.1136/rmdopen-2023-003440
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT04922840']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: KRN has received lecture honoraria from UCB. AGS has received lecture honoraria from Merck/Schering-Plough, BMS, UCB, Pfizer/Wyeth, Sanofi, Novartis, Pfizer and Lilly and is secretary of ESC Cardiovascular Pharmacotherapy working group.